Part 1: HER2-Positive Breast Cancer

Wednesday, December 7, 2022

• View Full Slide Presentation

• MODULE 1: Optimizing the Management of Localized HER2-Positive Breast Cancer — Dr Tolaney

• MODULE 2: Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer — Dr Krop

• MODULE 3: Management of HER2-Positive Breast Cancer with CNS Metastases — Dr Hamilton

• MODULE 4: Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer — Dr Modi

• MODULE 5: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Dr Hurvitz

Part 2: ER-Positive Breast Cancer

Thursday, December 8, 2022

• View Full Slide Presentation

• MODULE 1: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Goetz

• MODULE 2: Optimizing the Management of Localized ER-Positive Breast Cancer — Dr Kaklamani

• MODULE 3: Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC) — Dr Kalinsky

• MODULE 4: Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer — Dr Bardia

• MODULE 5: Novel Strategies Under Investigation for Patients with HR-Positive mBC — Dr Rugo